Emerging drug combinations to optimize renovascular protection and blood pressure goals

International Journal of Nephrology and Renovascular Disease

Volumn 5, Issue , 2012, Pages 69-80

  Escobar, Carlos ^a   Echarri, Rocio ^a   Barrios, Vivencio ^b  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Antihypertensive drugs; Combined therapy; Renin angiotensin system

Indexed keywords

ALISKIREN; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CILNIDIPINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LERCANIDIPINE; LISINOPRIL; LOSARTAN; MANIDIPINE; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL;

BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY DISEASE; LOW DRUG DOSE; METABOLIC DISORDER; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT; URINARY ELECTROLYTE WASTING;

EID: 84859460645     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S7048     Document Type: Review

References (84)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
2. Martínez-Castelao A, Górriz JL, Portolés JM, et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol. 2011;12:53.
3. Buckalew VM Jr, Berg RL, Wang SR, Porush JG, Rauch S, Schulman G. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis. 1996;28(6):811-821.
4. Deedwania PC. Hypertension and diabetes: new therapeutic options. Arch Intern Med. 2000;160(11):1585-1594.
5. Barrios V, Escobar C. Diabetes and hypertension: what is new? Minerva Cardioangiol. 2009;57(6):705-722.
6. Barrios V, Escobar C, Echarri R, de Alvaro F. New therapeutic progress in cardiorenal protection of the hypertensive patient with a focus on olmesartan. In: Volpe M, editor. Hot Topics in Hypertension. Vol 2. Modena, Italy: FB Communication; 2009(issue 8):1-24.
7. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary; Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28(19):2375-2414.
8. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85-97.
9. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799-805.
10. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1(1):8-18.
11. García-Donaire JA, Ruilope LM. Cardiovascular and renal links along the cardiorenal continuum. Int J Nephrol. 2011;2011:975782.
12. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629-636.
13. Ruilope KM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol. 2001;12(2):218-225.
14. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant. 1997;12(4):724-728.
15. Barrios V, Escobar C, Murga N, et al. Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice. J Hypertens. 2008;26(11):2230-2235.
16. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777-1782.
17. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjær H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study; the Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis. 2003;42(3):466-473.
18. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139(11):901-906.
19. Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant. 2006;21(9):2366-2374.
20. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease study. Kidney Int. 1997;51(6):1908-1919.
21. Morales E, Valero MA, León M, Hernández E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41(2):319-327.
22. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165(8):923-928.
23. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18.
24. Reynolds K, Gu D, Muntner P, et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. J Am Soc Nephrol. 2007;18(6):1928-1935.
25. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36(3):646-661.
26. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252.
27. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121-2158.
28. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. London: NICE; 2009. Available from: http://www.nice.org.uk/guidance/CG87.
29. Hackam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2. Therapy. Can J Cardiol. 2010;26(5):249-258.
30. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154(8):541-548.
31. Barrios V, Banegas JR, Ruilope LM, Rodicio JL. Evolution of blood pressure control in Spain. J Hypertens. 2007;25(9):1975-1977.
32. Barrios V, Escobar C, Calderón A, et al. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J Clin Hypertens (Greenwich). 2007;9(5):324-329.
33. Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol. 2010;24(1):3-8.
34. Volpe M. Angiotensin II: an amplifier of cardiovascular risk. Curr Hypertens Rep. 2004;6(4):247-248.
35. Schmieder RE, Ruilope LM, Barnett AH. Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol. 2011;24(5):569-580.
36. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116(4):263-272.
37. Fliser D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J Nephrol. 2010;23(4):369-376.
38. Campbell DJ, Woodward M, Chalmers JP, et al. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation. 2005;112(1):110-116.
39. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568):1208-1219.
40. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433-2446.
41. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941-1951.
42. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907-917.
43. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-259.
44. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
45. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
46. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
47. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978-2986.
48. Barrios V, Escobar C. Aliskiren in the management of hypertension. Am J Cardiovasc Drugs. 2010;10(6):349-358.
49. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809-2816.
50. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy: the GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857-1863.
51. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18(6):1889-1898.
52. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
53. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.
54. Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag. 2009;5(1):411-427.
55. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(12):1401-1409.
56. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347(16):1256-1261.
57. Abe M, Okada K, Maruyama T, Matsumoto K. Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease. Int J Clin Pharmacol Ther. 2009;47(8):525-532.
58. Abe M, Okada K, Maruyama T, Matsumoto K. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease. Pharmacotherapy. 2009;29(9):1061-1072.
59. Abe M, Okada K, Maruyama T, Matsumoto S, Matsumoto K. Blood pressure-lowering and antiproteinuric effect of switching from highdose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease. Int J Clin Pharmacol Ther. 2010;48(3):206-213.
60. Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/ indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension. 2003;41(5):1063-1071.
61. Patel A; ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-840.
62. Heerspink HJ. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway. Adv Chronic Kidney Dis. 2011;18(4):290-299.
63. Gojanovic B, Feihl F, Liaudet L, Waeber B. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotensin Aldosterone Syst. 2008;9(1):1-9.
64. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002;4(6):479-482.
65. Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers. Expert Rev Cardiovasc Ther. 2010;8(6):751-757.
66. Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc Ther. 2008;6(10):1347-1355.
67. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2CCchannel subtypes and pharmacology in the kidney. Circ Res. 2007;100(3):342-353.
68. Winer N, Folker A, Murphy JA, et al. Effect of fixed-dose ACE-inhibitor/ calcium channel blocker combination therapy vs ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005;8(2):87-92.
69. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15(12):1042-1049.
70. Fujita T, Ando K, Nishimura H, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72(12):1543-1549.
71. Egan CG, Pontremoli R. Role of the f ixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol. 2011;24(4): 428-437.
72. Barrios V, Navarro A, Esteras A, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice: the ELYPSE study; Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002;11(2):95-100.
73. Barrios V, Escobar C, de la Figuera M, et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE study. Cardiovasc Ther. 2008;26(1):2-9.
74. Barrios V, Escobar C, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study. Int J Clin Pract. 2006;60(11):1364-1370.
75. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004; 17(5):259-266.
76. Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005;27(1):73-80.
77. Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ. Treatment of proteinuria with lercanidipine associated with reninangiotensin axis-blocking drugs. Ren Fail. 2010;32(2):192-197.
78. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375(9721):1173-1181.
79. Barrios V, Escobar C. Antihypertensive and organ-protective effects of benazepril. Expert Rev Cardiovasc Ther. 2010;8(12):1653-1671.
80. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.
81. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care. 2005;28(2):273-277.
82. Tütüncü NB, Gürlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol. 2001;38(4):157-161.
83. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med. 2007;24(5): 486-493.
84. Maione A, Navaneethan SD, Graziano G, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011;26(9):2827-2847.